An interventional study of Valeda Light Delivery System and Valeda Light Delivery System Sham Mode in Dry Age-related Macular Degeneration, sponsored by LumiThera, Inc.. Completed at 10 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by LumiThera, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.
Among the 645 studies in Macular Degeneration with a site in United States, this one is the 176th largest by enrollment of the 491 interventional ones that give a count, is one of 33 that started in 2019, is one of 78 with no phase, and was the 430th registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 50+
Biojiva LLC · Sites in United States, Australia
Ages 55+
Sitala Bio LTD · Sites in United States, Argentina, Australia and 4 more countries
Ages 60+
Scott Raymond · Sites in United States
Ages 50–80
Astellas Institute for Regenerative Medicine · Sites in United States
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
645 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 152 · Phase 2 216 · Phase 3 103 · Phase 4 27
First in 1992; this study’s year is marked. 33 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 491 interventional studies, 100 across the 146 observational. Of the 464 that completed or were terminated, 183 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
375 of 645 have an industry lead sponsor. The 10 most frequent:
LumiThera, Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
LumiThera, Inc. has 6 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
36 of the studies in Macular Degeneration with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
| NCT06495918Phase 3Ocular Therapeutix, Inc.Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | 2027-01-08 |
| NCT06864988Phase 34D Molecular Therapeutics4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-06 |
| NCT05904028Phase 3Jaeb Center for Health ResearchHome OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD | 2027-07-30 |
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
Add all 36 to your calendar (.ics) → With an account.
Among the 645 studies in Macular Degeneration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD.
Alcon Research, LLC, acquired LumiThera in September 2025.
This study is a double-masked, sham-controlled, parallel design prospective, multi-site study on the use of photobiomodulation (PBM) as a treatment for visual impairment in subjects with dry AMD. Subjects will receive repeated sham or PBM treatments at several time-points throughout the 2-year study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of dry AMD as defined by the presence of the following:
Drusen that are intermediate in size or larger (63 μm or larger in diameter) with at least a few (3) being regular drusen and not pseudodrusen and/or geographic atrophy (GA) visible on two of the following: color fundus images, OCT and/or FAF, to be confirmed by the reading center
Exclusion Criteria:
Current or history of neovascular maculopathy that includes any of the following (to be confirmed by the reading center):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Valeda Light Delivery System: 3 PBM treatments per week over 3 to 5 weeks starting at Baseline and starting again at Months 4, 8, 12, 16 and 20.
Device: Valeda Light Delivery System
Valeda Light Delivery System Sham Mode: 3 sham treatments per week over 3 to 5 weeks starting at Baseline and starting again at Months 4, 8, 12, 16 and 20.
Device: Valeda Light Delivery System Sham Mode
Light delivery system that produces multi-wavelength LED treatment at 590, 660 and 850 nanometers.
Sham light delivery system that emits an approximate 50 times and 100 times reduction in treatment dose for the 590 and 660 nm wavelengths respectively and no emission of the 850 nm wavelength.
Mean Change From Baseline in Best Corrected Visual Acuity (Letters Read) at Month 21
Best Corrected Visual Acuity (BCVA) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) letter charts. Each line on the chart had exactly five letters, uniform spacing, and a proportional decrease in letter size, providing an equal level of difficulty for every single line read by the patient. A positive change in number of letters read indicates an improvement in visual acuity.
Time frame: Baseline (Day 0, pretreatment), Month 21
Mean Change From Baseline in Contrast Sensitivity (40 Centimeters) at Month 21
The Mars Contrast Sensitivity Test (Mars CS Test) is a vision test that measures how well a person can see objects that do not stand out clearly from their background. The test consisted of a set of charts that scored visual function from 0 (profound loss) to 1.92 (normal) vision at a distance of 40 centimeters. A positive change value indicates an improvement.
Time frame: Baseline (Day 0, pretreatment), Month 21
Mean Change From Baseline in Central Drusen Volume at Month 21
Drusen are yellowish deposits of lipids, cholesterol, and cellular waste products that accumulate underneath the retinal pigment epithelium (RPE). They are one of the hallmark signs of age-related macular degeneration (AMD). Central drusen volume is a measurement of the total amount of drusen material in the center of the retina (the macula). Central drusen volume was measured by optical coherence tomography and fundus autofluorescence imaging. A smaller change represents lesser damage to the retina.
Time frame: Baseline (Day 0, pretreatment), Month 21
Mean Change From Baseline in Low Luminance Best Corrected Visual Acuity (LLBCVA) at Month 21
Low Luminance Best Corrected Visual Acuity (BCVA) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) letter charts. A 2.0 log unit neutral density filter was added to create the low lighting conditions. Each line on the chart had exactly five letters, uniform spacing, and a proportional decrease in letter size, providing an equal level of difficulty for every single line read by the patient. A positive change in number of letters read indicates an improvement in visual acuity.
Time frame: Baseline (Day 0, pretreatment), Month 21
Mean Change From Baseline in VFQ-25 Composite Score at Month 21
VFQ-25 (National Eye Institute Visual Function Questionnaire-25, NEI VFQ-25) is a patient-reported outcome instrument designed to measure the impact of visual impairment on quality of life and daily functioning across 12 domains. Responses are recoded according to the official NEI scoring manual to a 0-100 scale, where 100 = best possible visual function/no impairment and 0 = worst possible visual function/maximum impairment. Intermediate response categories are transformed proportionally. The composite score is the sum of the 12 domains divided by 11. A composite score of 90-100 is considered minimal vision-related impairment; 70-89 is considered mild impairment; 50-69 is considered moderate impairment; and less than 50 is considered significant vision-related functional impairment. Positive change represents an improvement. This was a subject-based assessment and subject assigned a single score for both eyes.
Time frame: Baseline (Day 0, pretreatment), Month 21
Mean Change From Baseline in Radner Reading Speed at Month 21
Reading speed was assessed using the Radner Reading Chart, a standardized eye test that is used to measure a person's functional reading ability. The subject read short sentences in progressively smaller print while the examiner measured reading speed and accuracy. Reading speed (words per minute) was calculated as \[Number of correctly read words x 60\] / Reading time (seconds). A positive change in reading speed represents an improvement.
Time frame: Baseline (Day 0, pretreatment), Month 21
Mean Change From Baseline in Geographic Atrophy Lesion Area at Month 21
A geographic atrophy lesion (GA) is the specific area in the retina where the retina has thinned or disappeared due to GA, exposing deeper structures of the eye. GA lesion area was measured using fundus autofluorescence (FAF), a noninvasive eye imaging test that uses a camera to photograph the back of the eye and highlight damaged retinal cells. A smaller change in area from baseline represents slower legion growth (lesser damage to the retina).
Time frame: Baseline (Day 0, pretreatment), Month 21
Subjects were recruited and enrolled at 10 investigative sites located in the United States.
| Milestone | PBM Treatment | Sham Treatment |
|---|---|---|
| Started | 65 | 35 |
| Month 21 (mitt population) | 64 | 34 |
| Completed | 53 | 27 |
| Not completed | 12 | 8 |
| Withdrew: Withdrawal of consent | 8 | 4 |
| Withdrew: Unable to return to facility | 2 | 2 |
| Withdrew: Adverse event | 2 | 2 |
Best Corrected Visual Acuity (BCVA) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) letter charts. Each line on the chart had exactly five letters, uniform spacing, and a proportional decrease in letter size, providing an equal level of difficulty for every single line read by the patient. A positive change in number of letters read indicates an improvement in visual acuity.
| letters | PBM Treatment | Sham Treatment |
|---|---|---|
| Mean Change From Baseline in Best Corrected Visual Acuity (Letters Read) at Month 21 | 6.2 ± 1.02 | 2.4 ± 1.26 |
The Mars Contrast Sensitivity Test (Mars CS Test) is a vision test that measures how well a person can see objects that do not stand out clearly from their background. The test consisted of a set of charts that scored visual function from 0 (profound loss) to 1.92 (normal) vision at a distance of 40 centimeters. A positive change value indicates an improvement.
| score on a scale | PBM Treatment | Sham Treatment |
|---|---|---|
| Mean Change From Baseline in Contrast Sensitivity (40 Centimeters) at Month 21 | 0.03 ± 0.08 | 0.07 ± 0.07 |
Drusen are yellowish deposits of lipids, cholesterol, and cellular waste products that accumulate underneath the retinal pigment epithelium (RPE). They are one of the hallmark signs of age-related macular degeneration (AMD). Central drusen volume is a measurement of the total amount of drusen material in the center of the retina (the macula). Central drusen volume was measured by optical coherence tomography and fundus autofluorescence imaging. A smaller change represents lesser damage to the retina.
| mm3 | PBM Treatment | Sham Treatment |
|---|---|---|
| Mean Change From Baseline in Central Drusen Volume at Month 21 | 0.056 ± 0.01 | 0.098 ± 0.1 |
Low Luminance Best Corrected Visual Acuity (BCVA) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) letter charts. A 2.0 log unit neutral density filter was added to create the low lighting conditions. Each line on the chart had exactly five letters, uniform spacing, and a proportional decrease in letter size, providing an equal level of difficulty for every single line read by the patient. A positive change in number of letters read indicates an improvement in visual acuity.
| letters | PBM Treatment | Sham Treatment |
|---|---|---|
| Mean Change From Baseline in Low Luminance Best Corrected Visual Acuity (LLBCVA) at Month 21 | 3.1 ± 1.34 | 4.9 ± 1.58 |
VFQ-25 (National Eye Institute Visual Function Questionnaire-25, NEI VFQ-25) is a patient-reported outcome instrument designed to measure the impact of visual impairment on quality of life and daily functioning across 12 domains. Responses are recoded according to the official NEI scoring manual to a 0-100 scale, where 100 = best possible visual function/no impairment and 0 = worst possible visual function/maximum impairment. Intermediate response categories are transformed proportionally. The composite score is the sum of the 12 domains divided by 11. A composite score of 90-100 is considered minimal vision-related impairment; 70-89 is considered mild impairment; 50-69 is considered moderate impairment; and less than 50 is considered significant vision-related functional impairment. Positive change represents an improvement. This was a subject-based assessment and subject assigned a single score for both eyes.
| score on a scale | PBM Treatment | Sham Treatment |
|---|---|---|
| Mean Change From Baseline in VFQ-25 Composite Score at Month 21 | 1.5 ± 1.63 | -3.7 ± 2.02 |
Reading speed was assessed using the Radner Reading Chart, a standardized eye test that is used to measure a person's functional reading ability. The subject read short sentences in progressively smaller print while the examiner measured reading speed and accuracy. Reading speed (words per minute) was calculated as \[Number of correctly read words x 60\] / Reading time (seconds). A positive change in reading speed represents an improvement.
| words per minute | PBM Treatment | Sham Treatment |
|---|---|---|
| Mean Change From Baseline in Radner Reading Speed at Month 21 | -1.4 ± 9.5 | 0.6 ± 11.17 |
A geographic atrophy lesion (GA) is the specific area in the retina where the retina has thinned or disappeared due to GA, exposing deeper structures of the eye. GA lesion area was measured using fundus autofluorescence (FAF), a noninvasive eye imaging test that uses a camera to photograph the back of the eye and highlight damaged retinal cells. A smaller change in area from baseline represents slower legion growth (lesser damage to the retina).
| mm2 | PBM Treatment | Sham Treatment |
|---|---|---|
| Mean Change From Baseline in Geographic Atrophy Lesion Area at Month 21 | 2.06 ± 0.64 | 2.53 ± 0.91 |
Collected over Adverse events were collected from time of consent until study exit, approximately 24 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PBM Treatment | 0/65 (0%) | 7/93 (7.5%) | 1/93 (1.1%) |
| Sham Treatment | 0/35 (0%) | 3/55 (5.5%) | 4/55 (7.3%) |
| Event | PBM Treatment | Sham Treatment |
|---|---|---|
| Neovascular age-related macular degenerationEye disorders | 7/93 | 2/55 |
| Cystoid Macular EdemaEye disorders | 0/93 | 1/55 |
| Event | PBM Treatment | Sham Treatment |
|---|---|---|
| Vitreous FloatersEye disorders | 1/93 | 4/55 |
Safety Analysis Set: All qualifying eyes of subjects that signed the Informed Consent Form, were randomized, and received at least one study treatment.
| Age, Customized(years) | PBM Treatment | Sham Treatment | Total |
|---|---|---|---|
| Mean | 74.4 ± 7.3 | 77.1 ± 6.2 | 75.4 ± 7.1 |
| Sex: Female, Male(Participants) | PBM Treatment | Sham Treatment | Total |
|---|---|---|---|
| Female | 46 | 22 | 68 |
| Male | 19 | 13 | 32 |
| Ethnicity (NIH/OMB)(Participants) | PBM Treatment | Sham Treatment | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 6 |
| Not Hispanic or Latino | 62 | 32 | 94 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | PBM Treatment | Sham Treatment | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 65 | 34 | 99 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | PBM Treatment | Sham Treatment | Total |
|---|---|---|---|
| United States | 65 | 35 | 100 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2019 to primary completion in Jan 2023, 40 months.
Results were first posted in Oct 2026, 3 years 8 months after primary completion.
Of 133 interventional studies with no phase under Macular Degeneration, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 60. This study's 40 months is close to that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Jun 2022 → Jan 2023 and completion Jun 2022 → Nov 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
LumiThera, Inc.